Logo image of HRMY

HARMONY BIOSCIENCES HOLDINGS (HRMY) Stock Fundamental Analysis

NASDAQ:HRMY - US4131971040 - Common Stock

36.46 USD
-0.64 (-1.73%)
Last: 9/3/2025, 11:54:52 AM
Fundamental Rating

8

HRMY gets a fundamental rating of 8 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. HRMY gets an excellent profitability rating and is at the same time showing great financial health properties. HRMY is growing strongly while it also seems undervalued. This is an interesting combination These ratings could make HRMY a good candidate for value and growth and quality investing.


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

In the past year HRMY was profitable.
HRMY had a positive operating cash flow in the past year.
Of the past 5 years HRMY 4 years were profitable.
HRMY had a positive operating cash flow in 4 of the past 5 years.
HRMY Yearly Net Income VS EBIT VS OCF VS FCFHRMY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

1.2 Ratios

HRMY has a better Return On Assets (16.33%) than 95.38% of its industry peers.
HRMY has a better Return On Equity (23.40%) than 93.85% of its industry peers.
The Return On Invested Capital of HRMY (17.95%) is better than 95.90% of its industry peers.
HRMY had an Average Return On Invested Capital over the past 3 years of 18.27%. This is above the industry average of 15.28%.
Industry RankSector Rank
ROA 16.33%
ROE 23.4%
ROIC 17.95%
ROA(3y)19.12%
ROA(5y)10.08%
ROE(3y)31.57%
ROE(5y)9.53%
ROIC(3y)18.27%
ROIC(5y)15.29%
HRMY Yearly ROA, ROE, ROICHRMY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

HRMY has a better Profit Margin (23.42%) than 93.85% of its industry peers.
In the last couple of years the Profit Margin of HRMY has grown nicely.
HRMY has a better Operating Margin (28.72%) than 93.85% of its industry peers.
In the last couple of years the Operating Margin of HRMY has declined.
HRMY's Gross Margin of 78.34% is amongst the best of the industry. HRMY outperforms 85.64% of its industry peers.
In the last couple of years the Gross Margin of HRMY has remained more or less at the same level.
Industry RankSector Rank
OM 28.72%
PM (TTM) 23.42%
GM 78.34%
OM growth 3Y-2.32%
OM growth 5YN/A
PM growth 3Y21.57%
PM growth 5YN/A
GM growth 3Y-1.56%
GM growth 5Y1.26%
HRMY Yearly Profit, Operating, Gross MarginsHRMY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

8

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), HRMY is creating some value.
The number of shares outstanding for HRMY has been increased compared to 1 year ago.
HRMY has less shares outstanding than it did 5 years ago.
HRMY has a better debt/assets ratio than last year.
HRMY Yearly Shares OutstandingHRMY Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
HRMY Yearly Total Debt VS Total AssetsHRMY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

An Altman-Z score of 5.85 indicates that HRMY is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.85, HRMY is in the better half of the industry, outperforming 80.00% of the companies in the same industry.
HRMY has a debt to FCF ratio of 0.67. This is a very positive value and a sign of high solvency as it would only need 0.67 years to pay back of all of its debts.
HRMY's Debt to FCF ratio of 0.67 is amongst the best of the industry. HRMY outperforms 95.90% of its industry peers.
HRMY has a Debt/Equity ratio of 0.20. This is a healthy value indicating a solid balance between debt and equity.
HRMY has a Debt to Equity ratio of 0.20. This is comparable to the rest of the industry: HRMY outperforms 46.15% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF 0.67
Altman-Z 5.85
ROIC/WACC1.76
WACC10.19%
HRMY Yearly LT Debt VS Equity VS FCFHRMY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 3.84 indicates that HRMY has no problem at all paying its short term obligations.
The Current ratio of HRMY (3.84) is better than 62.56% of its industry peers.
A Quick Ratio of 3.80 indicates that HRMY has no problem at all paying its short term obligations.
With a decent Quick ratio value of 3.80, HRMY is doing good in the industry, outperforming 64.10% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.84
Quick Ratio 3.8
HRMY Yearly Current Assets VS Current LiabilitesHRMY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

8

3. Growth

3.1 Past

HRMY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 49.76%, which is quite impressive.
HRMY shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 44.61% yearly.
The Revenue has grown by 17.74% in the past year. This is quite good.
Measured over the past years, HRMY shows a very strong growth in Revenue. The Revenue has been growing by 160.13% on average per year.
EPS 1Y (TTM)49.76%
EPS 3Y44.61%
EPS 5YN/A
EPS Q2Q%240%
Revenue 1Y (TTM)17.74%
Revenue growth 3Y32.77%
Revenue growth 5Y160.13%
Sales Q2Q%16.01%

3.2 Future

HRMY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 39.17% yearly.
Based on estimates for the next years, HRMY will show a quite strong growth in Revenue. The Revenue will grow by 16.93% on average per year.
EPS Next Y27.74%
EPS Next 2Y26.66%
EPS Next 3Y27.32%
EPS Next 5Y39.17%
Revenue Next Year17.83%
Revenue Next 2Y17.29%
Revenue Next 3Y16.2%
Revenue Next 5Y16.93%

3.3 Evolution

The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
HRMY Yearly Revenue VS EstimatesHRMY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
HRMY Yearly EPS VS EstimatesHRMY Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 4 6 8 10

More info and screens

9

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 11.76, the valuation of HRMY can be described as reasonable.
HRMY's Price/Earnings ratio is rather cheap when compared to the industry. HRMY is cheaper than 89.23% of the companies in the same industry.
HRMY is valuated cheaply when we compare the Price/Earnings ratio to 26.90, which is the current average of the S&P500 Index.
HRMY is valuated reasonably with a Price/Forward Earnings ratio of 9.05.
Based on the Price/Forward Earnings ratio, HRMY is valued cheaply inside the industry as 87.18% of the companies are valued more expensively.
HRMY's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.52.
Industry RankSector Rank
PE 11.76
Fwd PE 9.05
HRMY Price Earnings VS Forward Price EarningsHRMY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, HRMY is valued cheaper than 94.36% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of HRMY indicates a rather cheap valuation: HRMY is cheaper than 92.82% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 8.11
EV/EBITDA 7.01
HRMY Per share dataHRMY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

HRMY's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of HRMY may justify a higher PE ratio.
A more expensive valuation may be justified as HRMY's earnings are expected to grow with 27.32% in the coming years.
PEG (NY)0.42
PEG (5Y)N/A
EPS Next 2Y26.66%
EPS Next 3Y27.32%

More info and screens

0

5. Dividend

5.1 Amount

HRMY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HARMONY BIOSCIENCES HOLDINGS

NASDAQ:HRMY (9/3/2025, 11:54:52 AM)

36.46

-0.64 (-1.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-05 2025-08-05/bmo
Earnings (Next)10-27 2025-10-27/bmo
Inst Owners80.56%
Inst Owner Change1.33%
Ins Owners0.56%
Ins Owner Change-0.12%
Market Cap2.10B
Analysts78.82
Price Target51.56 (41.42%)
Short Float %9.69%
Short Ratio7.44
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.92%
Min EPS beat(2)-11.17%
Max EPS beat(2)31%
EPS beat(4)3
Avg EPS beat(4)12.28%
Min EPS beat(4)-11.17%
Max EPS beat(4)31%
EPS beat(8)6
Avg EPS beat(8)59.09%
EPS beat(12)9
Avg EPS beat(12)123.49%
EPS beat(16)11
Avg EPS beat(16)86.61%
Revenue beat(2)0
Avg Revenue beat(2)-2.22%
Min Revenue beat(2)-3.46%
Max Revenue beat(2)-0.98%
Revenue beat(4)0
Avg Revenue beat(4)-1.79%
Min Revenue beat(4)-3.46%
Max Revenue beat(4)-0.91%
Revenue beat(8)1
Avg Revenue beat(8)-0.9%
Revenue beat(12)3
Avg Revenue beat(12)-1.17%
Revenue beat(16)4
Avg Revenue beat(16)-1.05%
PT rev (1m)1.7%
PT rev (3m)-0.67%
EPS NQ rev (1m)-11.77%
EPS NQ rev (3m)-14.4%
EPS NY rev (1m)-4.82%
EPS NY rev (3m)-2.25%
Revenue NQ rev (1m)0.79%
Revenue NQ rev (3m)0.27%
Revenue NY rev (1m)-0.3%
Revenue NY rev (3m)-0.21%
Valuation
Industry RankSector Rank
PE 11.76
Fwd PE 9.05
P/S 2.72
P/FCF 8.11
P/OCF 8.09
P/B 2.71
P/tB 3.12
EV/EBITDA 7.01
EPS(TTM)3.1
EY8.5%
EPS(NY)4.03
Fwd EY11.04%
FCF(TTM)4.49
FCFY12.32%
OCF(TTM)4.5
OCFY12.35%
SpS13.43
BVpS13.44
TBVpS11.68
PEG (NY)0.42
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 16.33%
ROE 23.4%
ROCE 23.91%
ROIC 17.95%
ROICexc 45.94%
ROICexgc 63.76%
OM 28.72%
PM (TTM) 23.42%
GM 78.34%
FCFM 33.46%
ROA(3y)19.12%
ROA(5y)10.08%
ROE(3y)31.57%
ROE(5y)9.53%
ROIC(3y)18.27%
ROIC(5y)15.29%
ROICexc(3y)40.78%
ROICexc(5y)37.48%
ROICexgc(3y)77.32%
ROICexgc(5y)N/A
ROCE(3y)24.34%
ROCE(5y)20.37%
ROICexcg growth 3Y-76.77%
ROICexcg growth 5YN/A
ROICexc growth 3Y-3.89%
ROICexc growth 5YN/A
OM growth 3Y-2.32%
OM growth 5YN/A
PM growth 3Y21.57%
PM growth 5YN/A
GM growth 3Y-1.56%
GM growth 5Y1.26%
F-Score6
Asset Turnover0.7
Health
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF 0.67
Debt/EBITDA 0.62
Cap/Depr 2.7%
Cap/Sales 0.08%
Interest Coverage 13.83
Cash Conversion 105.45%
Profit Quality 142.89%
Current Ratio 3.84
Quick Ratio 3.8
Altman-Z 5.85
F-Score6
WACC10.19%
ROIC/WACC1.76
Cap/Depr(3y)59.29%
Cap/Depr(5y)142.27%
Cap/Sales(3y)3.13%
Cap/Sales(5y)8.45%
Profit Quality(3y)125.93%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)49.76%
EPS 3Y44.61%
EPS 5YN/A
EPS Q2Q%240%
EPS Next Y27.74%
EPS Next 2Y26.66%
EPS Next 3Y27.32%
EPS Next 5Y39.17%
Revenue 1Y (TTM)17.74%
Revenue growth 3Y32.77%
Revenue growth 5Y160.13%
Sales Q2Q%16.01%
Revenue Next Year17.83%
Revenue Next 2Y17.29%
Revenue Next 3Y16.2%
Revenue Next 5Y16.93%
EBIT growth 1Y13.95%
EBIT growth 3Y29.68%
EBIT growth 5YN/A
EBIT Next Year48.18%
EBIT Next 3Y29.62%
EBIT Next 5Y26.74%
FCF growth 1Y60.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y60.46%
OCF growth 3Y30.64%
OCF growth 5YN/A